Furthermore, HER2 was shown to be selectively expressed in the cancer stem cell population of luminal ER + BC in the absence of HER2 gene amplification and provided evidence that the efficacy of HER2 blocking agents in the adjuvant setting may reflect effects on these cells [40]. The gene discussed is ESR1; the disease is breast cancer.